Insider Buying: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Major Shareholder Purchases $270,250.00 in Stock

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) major shareholder Braden Michael Leonard acquired 235,000 shares of the stock in a transaction that occurred on Thursday, June 27th. The stock was acquired at an average cost of $1.15 per share, for a total transaction of $270,250.00. Following the completion of the purchase, the insider now owns 11,787,134 shares in the company, valued at approximately $13,555,204.10. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Braden Michael Leonard also recently made the following trade(s):

• On Monday, July 1st, Braden Michael Leonard bought 107,434 shares of Aclaris Therapeutics stock. The stock was purchased at an average price of $1.14 per share, for a total transaction of $122,474.76.
• On Monday, June 17th, Braden Michael Leonard bought 150,000 shares of Aclaris Therapeutics stock. The stock was purchased at an average price of $1.13 per share, for a total transaction of $169,500.00.
• On Thursday, June 13th, Braden Michael Leonard bought 528,621 shares of Aclaris Therapeutics stock. The stock was purchased at an average price of $1.15 per share, for a total transaction of $607,914.15.
• On Tuesday, June 11th, Braden Michael Leonard bought 1,000,000 shares of Aclaris Therapeutics stock. The stock was purchased at an average price of $1.08 per share, for a total transaction of $1,080,000.00.

Aclaris Therapeutics Price Performance

Shares of ACRS stock opened at $1.15 on Thursday. The firm has a market cap of $81.95 million, a P/E ratio of -1.06 and a beta of 0.27. Aclaris Therapeutics, Inc. has a 1-year low of $0.59 and a 1-year high of $11.12. The firm’s 50-day simple moving average is $1.16 and its 200-day simple moving average is $1.17.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04. The business had revenue of $2.40 million for the quarter, compared to analyst estimates of $1.99 million. Aclaris Therapeutics had a negative net margin of 248.28% and a negative return on equity of 61.03%. Analysts expect that Aclaris Therapeutics, Inc. will post -0.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 2nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Aclaris Therapeutics has an average rating of “Hold” and an average target price of $22.25.

Institutional Trading of Aclaris Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC increased its position in Aclaris Therapeutics by 69.5% during the 1st quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 13,461 shares in the last quarter. Corton Capital Inc. acquired a new stake in Aclaris Therapeutics during the 3rd quarter worth approximately $102,000. Vontobel Holding Ltd. increased its position in Aclaris Therapeutics by 128.8% during the 4th quarter. Vontobel Holding Ltd. now owns 30,268 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 17,040 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Aclaris Therapeutics by 115.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,784 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 23,467 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in Aclaris Therapeutics by 10.9% during the 1st quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 23,747 shares in the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.